Who Will Benefit from the Darunavir Single-Tablet Regimen for HIV?
Magda Opsomer, MD, reveals who will benefit from the darunavir single-tablet HIV regimen.
Magda Opsomer, MD, director and clinical leader of Infectious Diseases and Vaccines at Janssen Pharmaceutical Companies, Belgium, reveals who will benefit from the darunavir single-tablet HIV regimen.
Recent Videos
Related Content
